Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: TF

Gene summary for TF

Gene summary.

Gene information	Species	Human
	Gene symbol	TF
	Gene ID	7018
	Gene name	transferrin
	Gene Alias	HEL-S-71p
	Cytomap	3q22.1
	Gene Type	protein-coding
	GO ID	GO:0000041
	UniProtAcc	A0PJA6

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
7018	TF	P8T-E	Human	Esophagus	ESCC	1.25e-10	4.06e-01	0.0889
7018	TF	P10T-E	Human	Esophagus	ESCC	1.42e-06	-5.41e-02	0.116
7018	TF	P16T-E	Human	Esophagus	ESCC	1.60e-16	2.50e-01	0.1153
7018	TF	P22T-E	Human	Esophagus	ESCC	2.40e-03	-8.78e-02	0.1236
7018	TF	P57T-E	Human	Esophagus	ESCC	9.24e-21	1.12e+00	0.0926
7018	TF	P74T-E	Human	Esophagus	ESCC	2.85e-03	1.43e-01	0.1479
7018	TF	P76T-E	Human	Esophagus	ESCC	5.67e-12	8.38e-01	0.1207
7018	TF	P128T-E	Human	Esophagus	ESCC	5.02e-19	1.31e+00	0.1241
7018	TF	NAFLD1	Human	Liver	NAFLD	1.33e-14	1.52e+00	-0.04
7018	TF	S43	Human	Liver	Cirrhotic	1.96e-06	4.81e-01	-0.0187
7018	TF	HCC1_Meng	Human	Liver	HCC	7.28e-77	1.16e+00	0.0246
7018	TF	HCC2_Meng	Human	Liver	HCC	6.25e-19	-6.79e-01	0.0107
7018	TF	cirrhotic1	Human	Liver	Cirrhotic	3.69e-15	-1.70e-01	0.0202
7018	TF	cirrhotic2	Human	Liver	Cirrhotic	1.67e-15	-1.87e-01	0.0201
7018	TF	cirrhotic3	Human	Liver	Cirrhotic	2.61e-02	-4.09e-01	0.0215
7018	TF	HCC1	Human	Liver	HCC	7.61e-40	8.09e+00	0.5336
7018	TF	HCC2	Human	Liver	HCC	6.48e-53	8.08e+00	0.5341
7018	TF	HCC5	Human	Liver	HCC	3.83e-07	4.78e+00	0.4932
7018	TF	Pt13.a	Human	Liver	HCC	1.44e-27	2.57e-01	0.021
7018	TF	Pt13.b	Human	Liver	HCC	8.21e-34	3.51e-02	0.0251

Page: 1 2

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:004668522	Skin	cSCC	response to arsenic-containing substance	24/4864	33/18723	2.54e-08	7.02e-07	24
GO:00905014	Skin	cSCC	RNA phosphodiester bond hydrolysis	71/4864	152/18723	2.72e-08	7.41e-07	71
GO:190198714	Skin	cSCC	regulation of cell cycle phase transition	150/4864	390/18723	3.21e-08	8.61e-07	150
GO:003459928	Skin	cSCC	cellular response to oxidative stress	117/4864	288/18723	3.37e-08	8.95e-07	117
GO:000635415	Skin	cSCC	DNA-templated transcription, elongation	48/4864	91/18723	4.58e-08	1.19e-06	48
GO:003009929	Skin	cSCC	myeloid cell differentiation	146/4864	381/18723	6.38e-08	1.61e-06	146
GO:000636815	Skin	cSCC	transcription elongation from RNA polymerase II promoter	39/4864	69/18723	7.15e-08	1.78e-06	39
GO:0010821111	Skin	cSCC	regulation of mitochondrion organization	67/4864	144/18723	7.99e-08	1.96e-06	67
GO:000661119	Skin	cSCC	protein export from nucleus	34/4864	57/18723	8.07e-08	1.96e-06	34
GO:000182413	Skin	cSCC	blastocyst development	53/4864	106/18723	9.74e-08	2.32e-06	53
GO:000626012	Skin	cSCC	DNA replication	106/4864	260/18723	1.18e-07	2.77e-06	106
GO:000698423	Skin	cSCC	ER-nucleus signaling pathway	29/4864	46/18723	1.33e-07	3.05e-06	29
GO:000762323	Skin	cSCC	circadian rhythm	89/4864	210/18723	1.55e-07	3.51e-06	89
GO:190589814	Skin	cSCC	positive regulation of response to endoplasmic reticulum stress	24/4864	35/18723	1.56e-07	3.51e-06	24
GO:000941114	Skin	cSCC	response to UV	68/4864	149/18723	1.62e-07	3.62e-06	68
GO:007149628	Skin	cSCC	cellular response to external stimulus	125/4864	320/18723	1.63e-07	3.65e-06	125
GO:0030968110	Skin	cSCC	endoplasmic reticulum unfolded protein response	40/4864	74/18723	2.52e-07	5.28e-06	40
GO:003464414	Skin	cSCC	cellular response to UV	46/4864	90/18723	2.95e-07	6.01e-06	46
GO:200123628	Skin	cSCC	regulation of extrinsic apoptotic signaling pathway	68/4864	151/18723	3.01e-07	6.12e-06	68
GO:0031334112	Skin	cSCC	positive regulation of protein-containing complex assembly	97/4864	237/18723	3.22e-07	6.51e-06	97

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0406629	Esophagus	ESCC	HIF-1 signaling pathway	75/4205	109/8465	3.66e-05	1.68e-04	8.60e-05	75
hsa043507	Esophagus	ESCC	TGF-beta signaling pathway	69/4205	108/8465	1.92e-03	5.54e-03	2.84e-03	69
hsa04066113	Esophagus	ESCC	HIF-1 signaling pathway	75/4205	109/8465	3.66e-05	1.68e-04	8.60e-05	75
hsa0435014	Esophagus	ESCC	TGF-beta signaling pathway	69/4205	108/8465	1.92e-03	5.54e-03	2.84e-03	69
hsa0421621	Liver	Cirrhotic	Ferroptosis	23/2530	41/8465	4.09e-04	2.57e-03	1.58e-03	23
hsa0406612	Liver	Cirrhotic	HIF-1 signaling pathway	46/2530	109/8465	4.00e-03	1.59e-02	9.78e-03	46
hsa0421631	Liver	Cirrhotic	Ferroptosis	23/2530	41/8465	4.09e-04	2.57e-03	1.58e-03	23
hsa0406613	Liver	Cirrhotic	HIF-1 signaling pathway	46/2530	109/8465	4.00e-03	1.59e-02	9.78e-03	46
hsa0421641	Liver	HCC	Ferroptosis	33/4020	41/8465	1.42e-05	9.88e-05	5.50e-05	33
hsa0406622	Liver	HCC	HIF-1 signaling pathway	70/4020	109/8465	2.96e-04	1.36e-03	7.57e-04	70
hsa0421651	Liver	HCC	Ferroptosis	33/4020	41/8465	1.42e-05	9.88e-05	5.50e-05	33
hsa0406632	Liver	HCC	HIF-1 signaling pathway	70/4020	109/8465	2.96e-04	1.36e-03	7.57e-04	70

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

SNV

Missense_Mutation

c.1906N>T

p.Gly636Cys

p.G636C

P02787

protein_coding

deleterious(0.01)

possibly_damaging(0.767)

TCGA-A2-A25A-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

Cytoxan

SNV

Missense_Mutation

novel

c.693N>T

p.Glu231Asp

p.E231D

P02787

protein_coding

tolerated(0.09)

benign(0.138)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

SNV

Missense_Mutation

c.1009N>C

p.Glu337Gln

p.E337Q

P02787

protein_coding

tolerated(0.24)

benign(0.03)

TCGA-AN-A0XW-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

SNV

Missense_Mutation

c.1565N>C

p.Leu522Pro

p.L522P

P02787

protein_coding

tolerated(0.35)

benign(0)

TCGA-AO-A128-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

SNV

Missense_Mutation

novel

c.1816N>C

p.Val606Leu

p.V606L

P02787

protein_coding

deleterious(0)

probably_damaging(0.979)

TCGA-B6-A0RG-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

SNV

Missense_Mutation

novel

c.1073G>T

p.Cys358Phe

p.C358F

P02787

protein_coding

deleterious(0.05)

benign(0.097)

TCGA-BH-A0BJ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

SNV

Missense_Mutation

novel

c.161N>T

p.Pro54Leu

p.P54L

P02787

protein_coding

tolerated(0.06)

possibly_damaging(0.843)

TCGA-BH-A0HF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

SNV

Missense_Mutation

c.1907N>T

p.Gly636Val

p.G636V

P02787

protein_coding

tolerated(0.05)

benign(0.375)

TCGA-BH-A18G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

SNV

Missense_Mutation

c.493C>G

p.Leu165Val

p.L165V

P02787

protein_coding

tolerated(0.45)

benign(0.035)

TCGA-EW-A1J5-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

insertion

Frame_Shift_Ins

novel

c.2011_2012insCCTCTGGGGGAACAACCACTCA

p.Gly671AlafsTer17

p.G671Afs*17

P02787

protein_coding

TCGA-A8-A07Z-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unspecific

Exemestane

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
7018	TF	CELL SURFACE, DRUGGABLE GENOME		adalimumab	ADALIMUMAB	27115882
7018	TF	CELL SURFACE, DRUGGABLE GENOME		Ademetionine	ADEMETIONINE
7018	TF	CELL SURFACE, DRUGGABLE GENOME		CALAA-01
7018	TF	CELL SURFACE, DRUGGABLE GENOME		PF-06763809
7018	TF	CELL SURFACE, DRUGGABLE GENOME		EP-2167

Page: 1